{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T12:11:08Z","timestamp":1711109468435},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1097\/maj.0b013e3181bae568","type":"journal-article","created":{"date-parts":[[2009,12,30]],"date-time":"2009-12-30T08:25:12Z","timestamp":1262161512000},"page":"86-88","source":"Crossref","is-referenced-by-count":2,"title":["Erythema Multiforme Associated With Gemfibrozil Monotherapy"],"prefix":"10.1016","volume":"339","author":[{"given":"Hamiyet Yilmaz","family":"Ya\u00e7sar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zden","family":"Ertu\u011frul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Co\u00e7skun","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1097\/MAJ.0b013e3181bae568_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199834020-00003","article-title":"Clinical pharmacokinetics of fibric acid derivatives (fibrates)","volume":"34","author":"Miller","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000063326","article-title":"Lipid-lowering drugs: are adverse effects predictable and reversible?","volume":"97","author":"Muscari","year":"2002","journal-title":"Cardiology"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0015","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1592\/phco.22.1.123.33501","article-title":"Sexual dysfunction secondary to gemfibrozil","volume":"22","author":"James","year":"2002","journal-title":"Pharmacotherapy"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0163-7258(98)00018-7","article-title":"Lipid-lowering drugs in the management of hyperlipidemia","volume":"79","author":"Bhatnagar","year":"1998","journal-title":"Pharmacol Ther"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0025","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/archinte.1991.00400090143027","article-title":"Gemfibrozil-induced myopathy","volume":"151","author":"Magarian","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1345\/aph.1D282","article-title":"Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy","volume":"38","author":"Layne","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0035","first-page":"1883","article-title":"Erythema multiforme","volume":"74","author":"Lamoreux","year":"2006","journal-title":"Am Fam Physician"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0040","first-page":"786","article-title":"Community pharmacist reporting of suspected ADRs: the first year of the yellow card demonstration scheme","volume":"263","author":"Davis","year":"1999","journal-title":"Pharm J"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0045","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1080\/15287390701601194","article-title":"Gemfibrozil ingestions reported to Texas poison control centers, 2000-2005","volume":"70","author":"Forrester","year":"2007","journal-title":"J Toxicol Environ Health A"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0050","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1172\/JCI10852","article-title":"Statin-induced inhibition ofthe Rho-signaling pathway activates PPAR-ct and induces HDL apoA-1","volume":"107","author":"Martin","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0055","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/00128071-200708060-00004","article-title":"Palmar erythema","volume":"8","author":"Serrao","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0060","first-page":"457","article-title":"Stevens-Johnson syndrome associated with bezafibrate","volume":"80","author":"Sawamura","year":"2000","journal-title":"Acta Derm Venereol"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2340\/0001555574475","article-title":"Stevens-Johnson syndrome induced by clofibrate","volume":"74","author":"Wong","year":"1994","journal-title":"Acta Derm Venereol"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0070","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2165\/00003495-199040020-00007","article-title":"Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia","volume":"40","author":"Balfour","year":"1990","journal-title":"Drugs"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0190-9622(88)80149-X","article-title":"Erythema multiforme due to clofibrate","volume":"18","author":"Murata","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.iac.2004.03.003","article-title":"Clinical evaluation and management of drug hypersensitivity","volume":"24","author":"Volcheck","year":"2004","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D37V35W30D","article-title":"Herpes simplex virus-associated erythema multiforme: a viral disease with an autoimmune component","volume":"9","author":"Aurelian","year":"2003","journal-title":"Dermatol Online J"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0090","first-page":"205","article-title":"Erythema multiforme to tetrazepam","volume":"17","author":"Ballesteros","year":"2007","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0095","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/00007611-200406000-00023","article-title":"Erythema multiforme associated with candesartan cilexetil","volume":"97","author":"Ejaz","year":"2004","journal-title":"South Med J"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1345\/aph.1E074","article-title":"Erythema multiforme from metformin","volume":"38","author":"Burger","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0105","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/art.20155","article-title":"Skin reaction to adali-mumab","volume":"50","author":"Beuthien","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0110","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S0025-6196(11)62421-X","article-title":"Bupropion-induced erythema multiforme","volume":"76","author":"Lineberry","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0190-9622(03)00478-X","article-title":"Stevens-Johnson syndrome associated with ciprofloxacin: a review of adverse cutaneous events reported in Sweden as associated with this drug","volume":"49","author":"Hallgren","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1097\/MAJ.0b013e3181bae568_bb0120","first-page":"82","article-title":"Metoprolol succinate therapy associated with erythema multiforme","volume":"16","author":"Hong","year":"2009","journal-title":"Cardiol J"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915317262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962915317262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:36:12Z","timestamp":1711107372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962915317262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0002962915317262"],"URL":"https:\/\/doi.org\/10.1097\/maj.0b013e3181bae568","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}